Ilumya (tildrakizumab)

pCPA File Number: 21496
Negotiation Status:
Concluded with an LOI
Indication(s):
Psoriasis, moderate to severe plaque
Sponsor/Manufacturer:
Sun Pharma Canada Inc.
CDA-AMC Project Number:
SR0624
pCPA Engagement Letter Issued:
Negotiation Process Concluded: